Search > Results
You searched for: EV170037 (EV-TRACK ID)
Showing 1 - 3 of 3
Showing 1 - 3 of 3
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV170037 | 1/3 | Homo sapiens | Serum | (d)(U)C | Klump, Jennifer | 2018 | 28% | |
Study summaryFull title
All authors
Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, von Bubnoff N, Nazarenko I
Journal
Nanomedicine
Abstract
Clinical evidence in oncology argues for the advantages of performing molecular analysis of blood bi (show more...)
EV-METRIC
28% (70th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
213.2 (pelleting) / 213.2 (washing)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Wash: time (min)
120
Wash: Rotor Type
SW 41 Ti
Wash: speed (g)
120000
Wash: adjusted k-factor
213.2
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
10-50 dependent whether healthy donors or cancer patients were analyzed
Characterization: Lipid analysis
No
Characterization: Particle analysis
DLS
Report type
Size range/distribution
Reported size (nm)
different populations of vesicles were detected by DLS and NTA;120-500 nm; and over 1000 nm
NTA
Report type
Size range/distribution
Reported size (nm)
90-300
EV concentration
Yes
Particle yield
3.00E+09 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Report size (nm)
90-120
Extra information
Publication aimed to determine the content of mutated DNA oncogenes copy inside of the vesicles (post- DNase treatments) and in the free-circulating fractions. For that DNA was isolated from different EV and fc fractions and DNA was analyzed using ddPCR. Conclusion was that the mutated BRAF and c-KIT copies are preferably located in the free-circulating fractions and not in EVs.
|
||||||||
EV170037 | 2/3 | Homo sapiens | Serum | (d)(U)C | Klump, Jennifer | 2018 | 28% | |
Study summaryFull title
All authors
Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, von Bubnoff N, Nazarenko I
Journal
Nanomedicine
Abstract
Clinical evidence in oncology argues for the advantages of performing molecular analysis of blood bi (show more...)
EV-METRIC
28% (70th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Melanoma
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
213.2 (pelleting) / 213.2 (washing)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Wash: time (min)
120
Wash: Rotor Type
SW 41 Ti
Wash: speed (g)
120000
Wash: adjusted k-factor
213.2
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
10-50 dependent whether healthy donors or cancer patients were analyzed
Characterization: Lipid analysis
No
Characterization: Particle analysis
DLS
Report type
Size range/distribution
Reported size (nm)
different populations of vesicles were detected by DLS and NTA;120-500 nm; and over 1000 nm
NTA
Report type
Size range/distribution
Reported size (nm)
90-300
EV concentration
Yes
Particle yield
3.00E+09 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Report size (nm)
90-120
Extra information
Publication aimed to determine the content of mutated DNA oncogenes copy inside of the vesicles (post- DNase treatments) and in the free-circulating fractions. For that DNA was isolated from different EV and fc fractions and DNA was analyzed using ddPCR. Conclusion was that the mutated BRAF and c-KIT copies are preferably located in the free-circulating fractions and not in EVs.
|
||||||||
EV170037 | 3/3 | Homo sapiens | Serum | (d)(U)C | Klump, Jennifer | 2018 | 28% | |
Study summaryFull title
All authors
Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, von Bubnoff N, Nazarenko I
Journal
Nanomedicine
Abstract
Clinical evidence in oncology argues for the advantages of performing molecular analysis of blood bi (show more...)
EV-METRIC
28% (70th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Mastocytosis
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
Adj. k-factor
213.2 (pelleting) / 213.2 (washing)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Wash: time (min)
120
Wash: Rotor Type
SW 41 Ti
Wash: speed (g)
120000
Wash: adjusted k-factor
213.2
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
10-50 dependent whether healthy donors or cancer patients were analyzed
Characterization: Lipid analysis
No
Characterization: Particle analysis
DLS
Report type
Size range/distribution
Reported size (nm)
different populations of vesicles were detected by DLS and NTA;120-500 nm; and over 1000 nm
NTA
Report type
Size range/distribution
Reported size (nm)
90-300
EV concentration
Yes
Particle yield
3.00E+09 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Report size (nm)
90-120
Extra information
Publication aimed to determine the content of mutated DNA oncogenes copy inside of the vesicles (post- DNase treatments) and in the free-circulating fractions. For that DNA was isolated from different EV and fc fractions and DNA was analyzed using ddPCR. Conclusion was that the mutated BRAF and c-KIT copies are preferably located in the free-circulating fractions and not in EVs.
|
||||||||
1 - 3 of 3 |
EV-TRACK ID | EV170037 | ||
---|---|---|---|
species | Homo sapiens | ||
sample type | Serum | ||
condition | Control condition | Melanoma | Mastocytosis |
separation protocol | (d)(U)C | (d)(U)C | (d)(U)C |
Exp. nr. | 1 | 2 | 3 |
EV-METRIC % | 28 | 28 | 28 |